Novavax Inc. (NASDAQ: NVAX) just checked another box on its list toward broadening its Covid-19 vaccine’s availability in the U.S.
The company has earned the Centers for Disease Control and Prevention’s recommendation to expand the use of its protein-based shot to adolescents ages 12 through 17. The CDC said Monday that its director, Dr. Rochelle Walensky, signed off on the decision for Novavax’s vaccine to “be used as another primary series option” for this age group.
It comes just…
